Navigated to Brello Health: GLP-1 Costs, Billing and Commitment
Skip to main content
GLP1 Buyer Guide
All ranked programsProvider profile
Compounded products2 recorded medications

Brello Health

Brello Health is recorded on 2 offers in this comparison, covering semaglutide, tirzepatide. Each plan is recorded separately with its own charge, cadence and commitment.

By Open Water Rx Editorial Team, Publisher and buyer-guide research

Price sources checked
Buyer Guide ScoreMethod
71.7/100
Strong

Ranked 46 of 67 programs in the buyer guide index.

Price98/100
Fee transparency50/100
Cadence certainty100/100
Terms on record100/100

Each criterion is rated on its own out of 100. The headline score is the publisher’s overall judgment; it is not an average of these four readings.

Tirzepatide
$499Recorded plan charge
Semaglutide
$399Recorded plan charge
Membership
Not statedNot stated on the provider page
Commitment
Auto-renewsThe term recorded on the plan

Supported tradeoffs

The marketed three-month plan and 77-day renewal interval are different fields. Do not infer a 90-day supply or treat the headline as a monthly charge.

Billing and cancellation

The advertised three-month plans charge $399 for semaglutide or $499 for tirzepatide, then repeat every 11 weeks.

Availability

The supported-state list is not established for this program, so the field is left blank rather than assumed.

Availability is set program by program by prescriber licensure, pharmacy fulfillment and state rules, so it can change after a directory is published. A provider state directory is not a fulfillment guarantee, and where a supported-state list is not established the field is left blank rather than assumed.

Recorded pricing changes

Documented shifts in this provider's own published figures, kept with the date we recorded them. Older material is flagged rather than silently overwritten.

  • Six-month plan now advertised

    Three-month marketed plan only, at $499 for tirzepatide every 11 weeksSix-month plan advertised at $894 for tirzepatide, about $149 a month

    Recorded October 23, 2026. The six-month plan is a longer prepaid term and is not recorded as a monthly offer. It is noted here so the three-month rate is not mistaken for the only structure the provider sells.

See all recorded changes on the corrections page.

Offer terms in detail

Every field the record carries for each plan, with the date the provider page behind it was checked.

SemaglutideCompounded · not FDA-approved

Three-month marketed plan; 11-week billing

5 recorded source entries · last checked October 22, 2026.

Recurring charge

$399

Recurring

Formulation
Compounded injectable
Initial payment
$399 · At checkout before the health review.
Billing cadence
Recurring
Supply period
Marketed as a 3-month plan; exact day supply not established
Commitment
Auto-renews on the recorded billing cadence until canceled. Each charge covers 3 months as published. The minimum term is not established from the reviewed terms; the cancellation conditions are recorded on this offer.
Required fees
No standard extra fees are recorded. Conditional: $50 retained in the eligible post-prescription cancellation window.
Conditional fees
$50 retained in the eligible post-prescription cancellation window.
Inclusions
Medication if approved, supplies, provider review, shipping and program access.
Dose scope
Provider-selected; numeric range not established
Eligibility
Subject to provider approval and availability
Cancellation
Turn off future orders using the account cancellation control; cancellation of a paid order depends on its processing stage.
Refunds
Full refund before review or if declined. After prescription but before dispensing: refund less $50 only if emailed within 24 hours of prescription notification. No routine refund after dispensing.
Limitations
The marketed three-month plan and 77-day renewal interval are different fields. Do not infer a 90-day supply or treat the headline as a monthly charge.
Offers excluded from this release
[]
Verification
published price and billing terms · recheck due October 29, 2026
TirzepatideCompounded · not FDA-approved

Three-month marketed plan; 11-week billing

5 recorded source entries · last checked October 22, 2026.

Recurring charge

$499

Recurring

Formulation
Compounded injectable
Initial payment
$499 · At checkout before the health review.
Billing cadence
Recurring
Supply period
Marketed as a 3-month plan; exact day supply not established
Commitment
Auto-renews on the recorded billing cadence until canceled. Each charge covers 3 months as published. The minimum term is not established from the reviewed terms; the cancellation conditions are recorded on this offer.
Required fees
No standard extra fees are recorded. Conditional: $50 retained in the eligible post-prescription cancellation window.
Conditional fees
$50 retained in the eligible post-prescription cancellation window.
Inclusions
Medication if approved, supplies, provider review, shipping and program access.
Dose scope
Provider-selected; numeric range not established
Eligibility
Subject to provider approval and availability
Cancellation
Turn off future orders using the account cancellation control; cancellation of a paid order depends on its processing stage.
Refunds
Full refund before review or if declined. After prescription but before dispensing: refund less $50 only if emailed within 24 hours of prescription notification. No routine refund after dispensing.
Verification
published price and billing terms · recheck due October 29, 2026

Cost and verification scope

Semaglutide · Tirzepatide

Published standard plan bundle; conditional charges are described in provider terms

Published pricing and billing terms; no purchase, clinical, licensing or fulfillment audit

Last checked

Most recent check date

October 22, 2026

The newest date we checked Brello Health's own published pages. A figure we could not check carries no date rather than an unverified one, and this research reads published pages, not checkout transactions.

How sources are checked

Every recorded offer, side by side with the others: the comparison ledger.

Back to the provider directory
FAQ

Questions about Brello Health

How to read the fields, the sources and the labels on this profile.

  • It means no reliable figure exists yet for that field on this provider, so we leave it blank instead of guessing. A field becomes a published value only when a page on this provider supports it.

Last modified . Facts carry the date we checked the provider page behind them.